Are weight loss tablets as effective as injections — and how do you choose?

You've heard there's finally a tablet option, here's where it sits

Imagine you've been reading about Wegovy tablets since the MHRA approved them in June 2026, and you're quietly relieved. No needles. No fridge to manage. Just a tablet before breakfast. The question you actually want answered isn't whether tablets exist, it's whether the convenience costs you anything in results.

The answer is nuanced. The OASIS 4 phase 3 trial followed 307 adults with obesity or overweight plus at least one weight-related condition for 64 weeks. Participants taking 25 mg oral semaglutide lost an average of roughly 13.6% of their body weight, compared with about 2.4% on placebo. Among those who were fully adherent throughout, the figure was closer to 16.6%. That framing matters, the overall average is the right number for most people to plan around, while the adherence-specific figure tells you what's possible when the regimen is followed closely. The trial results are published alongside the Novo Nordisk UK approval materials; the NHS semaglutide medicines page carries the headline information for patients.

So tablets work. The question is whether they work as well as injections, and that's where the comparison gets more specific. A detailed side-by-side of tablets and injections is worth reading if you're at the decision point, because dose form is only one of the variables.

Where injections pull ahead (and where they don't

Wegovy injection, the weekly subcutaneous semaglutide pen, averaged around 15% weight loss in the STEP 1 trial over 68 weeks) a modest lead over the tablet's overall average, but smaller than many people expect. The meaningful jump comes with Mounjaro (tirzepatide), which works on two gut-hormone receptors rather than one. In SURMOUNT-1, a 72-week trial involving 2,539 adults with obesity, participants on the 15 mg dose lost an average of around 20–21% of their body weight, as published in the New England Journal of Medicine. NICE's appraisal of tirzepatide (TA1026) noted in its committee discussion that indirect comparisons favoured tirzepatide over semaglutide 2.4 mg.

That said, averages are not predictions. Someone who finds the injection routine difficult to sustain consistently may do better on a tablet they actually take every morning. Real-world adherence shapes real-world results far more than a 3–5 percentage-point difference in trial means.

There's also a practical point worth raising: the injection arrives in a pre-filled pen, tracked through DPD the next working day, in plain unbranded packaging. For a lot of people, that first delivery makes the pen feel far less clinical than they'd imagined. But if weekly injections are genuinely off the table for you (needle anxiety, certain skin conditions, a lifestyle where refrigeration is tricky) the tablet is a licensed, evidence-backed alternative, not a consolation prize. If you're weighing up the two formats, our guide to whether weight loss tablets are as good as injections looks at the evidence in detail. You can read more about whether tablets work as well as injections for specific situations.

The differences that matter beyond the headline percentage

Results are one dimension. Several others shape which form suits a given person.

How you take it. The Wegovy tablet goes under a specific set of rules: first thing in the morning, with a small amount of plain water, at least 30 minutes before any food, drink or other oral medicines. Miss that window and absorption drops. The injection has a broader weekly window, any day, any time of day, consistent if possible but flexible if not. Neither is especially burdensome, but they suit different routines.

Storage. The tablet needs no refrigeration, which matters for frequent travellers or anyone without reliable fridge access. Injections should be stored at 2–8°C and have a limited room-temperature window once removed, the exact window is in the Patient Information Leaflet and should be followed. The weight-loss injections overview covers storage and practical preparation in more detail.

Side-effect profile. Both forms share a GI-led side-effect pattern (nausea, loose stools, indigestion) because they work through the same hormonal pathways. In the OASIS 4 trial, gastrointestinal side effects were reported by 74% of participants on the oral form versus 42% on placebo, suggesting the tablet may produce slightly more GI symptoms than the injection, though direct head-to-head safety comparisons don't yet exist. A closer look at whether weight loss pills are as effective as injections covers this side-effect gap alongside the efficacy picture. Effects typically settle within a few days to a couple of weeks as the body adjusts. Serious side effects are uncommon; the MHRA Yellow Card scheme lets anyone report a suspected reaction directly.

What the prescriber factors in. Other medicines you take, existing health conditions, your starting BMI, and how you've responded to treatment before all feed into the clinical picture. The tablet's absorption can be affected by anything that alters gastric emptying or stomach pH, relevant if you take certain other oral medicines. A prescriber reviews all of this before any decision is made. If you'd like to know more about what the assessment involves, our FAQs address common questions about the process.

So which should you choose?

The clinical evidence doesn't give one form a decisive win. For maximum average weight loss, Mounjaro injection leads. For those who want to avoid injections entirely, the oral Wegovy tablet is a licensed UK option with meaningful trial evidence behind it. Wegovy injection sits between the two on average results.

The more useful question is: which form fits your life well enough to stay on consistently, at the doses your prescriber recommends, for the duration that achieves a clinical benefit? That's a clinical conversation, not a product choice. Our clinical team at nume reviews every consultation personally, a real prescriber reads your answers, considers your medical history, and makes a recommendation based on your situation specifically. You can explore your options and start your free consultation if you're ready to take the next step.